AAPL312.66+4.03 (+1.31%) ▲|ABBV254.76-6.31 (-2.42%) ▼|ABT95.63+0.23 (+0.24%) ▲|ACN136.96-0.39 (-0.28%) ▼|ADBE218.07-1.65 (-0.75%) ▼|AMAT592.79-10.25 (-1.70%) ▼|AMD552.05+34.23 (+6.61%) ▲|AMGN366.44-7.71 (-2.06%) ▼|AMT162.11-3.92 (-2.36%) ▼|AMZN244.16+1.49 (+0.61%) ▲|AVGO373.90+13.45 (+3.73%) ▲|AXP356.03+4.07 (+1.16%) ▲|BA234.54+8.05 (+3.55%) ▲|BAC59.90+1.17 (+1.99%) ▲|BKNG181.03-3.53 (-1.91%) ▼|BLK1,011.21+15.48 (+1.55%) ▲|BMY56.70-1.43 (-2.46%) ▼|BNY149.96+3.34 (+2.28%) ▲|BRK-B506.58-1.20 (-0.24%) ▼|C143.86+3.89 (+2.78%) ▲|CAT969.92+6.39 (+0.66%) ▲|CL93.39-1.74 (-1.83%) ▼|CMCSA23.38-0.41 (-1.72%) ▼|COF206.50+1.38 (+0.67%) ▲|COP103.58-1.15 (-1.10%) ▼|COST950.25-1.42 (-0.15%) ▼|CRM165.65-0.46 (-0.28%) ▼|CSCO113.98+1.29 (+1.14%) ▲|CVS102.08-2.64 (-2.52%) ▼|CVX168.10-1.10 (-0.65%) ▼|DE635.24+13.97 (+2.25%) ▲|DHR193.62-4.31 (-2.18%) ▼|DIS97.41-2.09 (-2.10%) ▼|DUK125.97-3.63 (-2.80%) ▼|EMR141.56+2.51 (+1.81%) ▲|FDX309.93-3.07 (-0.98%) ▼|GD376.88+3.34 (+0.89%) ▲|GE378.68+1.63 (+0.43%) ▲|GEV1,152.04+38.93 (+3.50%) ▲|GILD129.61-1.66 (-1.26%) ▼|GM77.85+1.85 (+2.43%) ▲|GOOG364.90+8.72 (+2.45%) ▲|GOOGL366.46+6.55 (+1.82%) ▲|GS1,055.29+34.29 (+3.36%) ▲|HD350.65-7.25 (-2.03%) ▼|HON231.18+1.32 (+0.57%) ▲|IBM299.52+10.00 (+3.45%) ▲|INTC122.20+1.85 (+1.54%) ▲|INTU272.14-3.21 (-1.17%) ▼|ISRG432.83+6.82 (+1.60%) ▲|JNJ259.33-3.71 (-1.41%) ▼|JPM337.72+4.75 (+1.43%) ▲|KO82.96-1.18 (-1.40%) ▼|LIN540.52-6.12 (-1.12%) ▼|LLY1,200.06-13.85 (-1.14%) ▼|LMT538.00-7.91 (-1.45%) ▼|LOW223.78-3.72 (-1.64%) ▼|LRCX350.20-1.21 (-0.34%) ▼|MA533.10-6.29 (-1.17%) ▼|MCD279.50-1.13 (-0.40%) ▼|MDLZ59.17-1.74 (-2.86%) ▼|MDT83.06-0.13 (-0.16%) ▼|META600.29+17.39 (+2.98%) ▲|MMM159.15-1.29 (-0.80%) ▼|MO71.88-0.83 (-1.14%) ▼|MRK126.78-2.78 (-2.15%) ▼|MS222.10+8.17 (+3.82%) ▲|MSFT386.74-3.75 (-0.96%) ▼|MU984.75+9.19 (+0.94%) ▲|NEE87.44-0.90 (-1.02%) ▼|NFLX76.02-1.63 (-2.10%) ▼|NKE43.34-0.75 (-1.70%) ▼|NOW107.93+1.61 (+1.51%) ▲|NVDA195.55+0.72 (+0.37%) ▲|ORCL143.76+3.49 (+2.49%) ▲|PEP143.29-0.93 (-0.64%) ▼|PFE23.72-0.60 (-2.47%) ▼|PG149.31-2.10 (-1.39%) ▼|PLTR132.54+3.24 (+2.51%) ▲|PM184.76+2.49 (+1.37%) ▲|QCOM186.48+10.23 (+5.80%) ▲|RTX201.37+2.12 (+1.06%) ▲|SBUX102.11-2.16 (-2.07%) ▼|SCHW100.62+3.62 (+3.73%) ▲|SO95.99-1.99 (-2.03%) ▼|SPG225.00-1.06 (-0.47%) ▼|T20.58+0.00 (+0.00%) ▲|TMO517.60-5.84 (-1.12%) ▼|TMUS181.79+4.27 (+2.41%) ▲|TSLA419.77+26.32 (+6.69%) ▲|TXN303.50+10.42 (+3.56%) ▲|UBER72.42-2.01 (-2.70%) ▼|UNH417.99-7.37 (-1.73%) ▼|UNP282.59+0.34 (+0.12%) ▲|UPS110.02-0.64 (-0.58%) ▼|USB62.83+1.10 (+1.78%) ▲|V357.25-4.88 (-1.35%) ▼|VZ42.07-0.49 (-1.15%) ▼|WFC87.45+1.94 (+2.27%) ▲|WMT110.65-1.19 (-1.06%) ▼|XOM136.44-0.65 (-0.47%) ▼|AAPL312.66+4.03 (+1.31%) ▲|ABBV254.76-6.31 (-2.42%) ▼|ABT95.63+0.23 (+0.24%) ▲|ACN136.96-0.39 (-0.28%) ▼|ADBE218.07-1.65 (-0.75%) ▼|AMAT592.79-10.25 (-1.70%) ▼|AMD552.05+34.23 (+6.61%) ▲|AMGN366.44-7.71 (-2.06%) ▼|AMT162.11-3.92 (-2.36%) ▼|AMZN244.16+1.49 (+0.61%) ▲|AVGO373.90+13.45 (+3.73%) ▲|AXP356.03+4.07 (+1.16%) ▲|BA234.54+8.05 (+3.55%) ▲|BAC59.90+1.17 (+1.99%) ▲|BKNG181.03-3.53 (-1.91%) ▼|BLK1,011.21+15.48 (+1.55%) ▲|BMY56.70-1.43 (-2.46%) ▼|BNY149.96+3.34 (+2.28%) ▲|BRK-B506.58-1.20 (-0.24%) ▼|C143.86+3.89 (+2.78%) ▲|CAT969.92+6.39 (+0.66%) ▲|CL93.39-1.74 (-1.83%) ▼|CMCSA23.38-0.41 (-1.72%) ▼|COF206.50+1.38 (+0.67%) ▲|COP103.58-1.15 (-1.10%) ▼|COST950.25-1.42 (-0.15%) ▼|CRM165.65-0.46 (-0.28%) ▼|CSCO113.98+1.29 (+1.14%) ▲|CVS102.08-2.64 (-2.52%) ▼|CVX168.10-1.10 (-0.65%) ▼|DE635.24+13.97 (+2.25%) ▲|DHR193.62-4.31 (-2.18%) ▼|DIS97.41-2.09 (-2.10%) ▼|DUK125.97-3.63 (-2.80%) ▼|EMR141.56+2.51 (+1.81%) ▲|FDX309.93-3.07 (-0.98%) ▼|GD376.88+3.34 (+0.89%) ▲|GE378.68+1.63 (+0.43%) ▲|GEV1,152.04+38.93 (+3.50%) ▲|GILD129.61-1.66 (-1.26%) ▼|GM77.85+1.85 (+2.43%) ▲|GOOG364.90+8.72 (+2.45%) ▲|GOOGL366.46+6.55 (+1.82%) ▲|GS1,055.29+34.29 (+3.36%) ▲|HD350.65-7.25 (-2.03%) ▼|HON231.18+1.32 (+0.57%) ▲|IBM299.52+10.00 (+3.45%) ▲|INTC122.20+1.85 (+1.54%) ▲|INTU272.14-3.21 (-1.17%) ▼|ISRG432.83+6.82 (+1.60%) ▲|JNJ259.33-3.71 (-1.41%) ▼|JPM337.72+4.75 (+1.43%) ▲|KO82.96-1.18 (-1.40%) ▼|LIN540.52-6.12 (-1.12%) ▼|LLY1,200.06-13.85 (-1.14%) ▼|LMT538.00-7.91 (-1.45%) ▼|LOW223.78-3.72 (-1.64%) ▼|LRCX350.20-1.21 (-0.34%) ▼|MA533.10-6.29 (-1.17%) ▼|MCD279.50-1.13 (-0.40%) ▼|MDLZ59.17-1.74 (-2.86%) ▼|MDT83.06-0.13 (-0.16%) ▼|META600.29+17.39 (+2.98%) ▲|MMM159.15-1.29 (-0.80%) ▼|MO71.88-0.83 (-1.14%) ▼|MRK126.78-2.78 (-2.15%) ▼|MS222.10+8.17 (+3.82%) ▲|MSFT386.74-3.75 (-0.96%) ▼|MU984.75+9.19 (+0.94%) ▲|NEE87.44-0.90 (-1.02%) ▼|NFLX76.02-1.63 (-2.10%) ▼|NKE43.34-0.75 (-1.70%) ▼|NOW107.93+1.61 (+1.51%) ▲|NVDA195.55+0.72 (+0.37%) ▲|ORCL143.76+3.49 (+2.49%) ▲|PEP143.29-0.93 (-0.64%) ▼|PFE23.72-0.60 (-2.47%) ▼|PG149.31-2.10 (-1.39%) ▼|PLTR132.54+3.24 (+2.51%) ▲|PM184.76+2.49 (+1.37%) ▲|QCOM186.48+10.23 (+5.80%) ▲|RTX201.37+2.12 (+1.06%) ▲|SBUX102.11-2.16 (-2.07%) ▼|SCHW100.62+3.62 (+3.73%) ▲|SO95.99-1.99 (-2.03%) ▼|SPG225.00-1.06 (-0.47%) ▼|T20.58+0.00 (+0.00%) ▲|TMO517.60-5.84 (-1.12%) ▼|TMUS181.79+4.27 (+2.41%) ▲|TSLA419.77+26.32 (+6.69%) ▲|TXN303.50+10.42 (+3.56%) ▲|UBER72.42-2.01 (-2.70%) ▼|UNH417.99-7.37 (-1.73%) ▼|UNP282.59+0.34 (+0.12%) ▲|UPS110.02-0.64 (-0.58%) ▼|USB62.83+1.10 (+1.78%) ▲|V357.25-4.88 (-1.35%) ▼|VZ42.07-0.49 (-1.15%) ▼|WFC87.45+1.94 (+2.27%) ▲|WMT110.65-1.19 (-1.06%) ▼|XOM136.44-0.65 (-0.47%) ▼|
17.9 C
New York
Tuesday, July 7, 2026

Tag: research

newssourceFORcompanyinformationcontent1releasesmarket

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Antigen Security Announces Collaboration with Microsoft to Offer Up to 60% Savings on Cyber Insurance Premiums

FLINT, Mich., June 26, 2025 /PRNewswire/ -- Antigen Security, LLC ("Antigen") today announced a new partner program with Microsoft, affirming Antigen as one of...

Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain

ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- A new survey of 195 diagnostic imaging and clinical lab professionals reveals that tariff policy uncertainty is...

Space Fiesta 2025 Lights Up Albuquerque with Innovation, Art, and Economic Momentum

ALBUQUERQUE, N.M., June 26, 2025 /PRNewswire/ -- Space Fiesta 2025, the highly anticipated fusion of science, technology, entrepreneurship and creative culture in the space...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

American Outdoor Brands, Inc. Reports Fourth Quarter and Full Fiscal 2025 Financial Results

•  FY25 Net Sales $222.3 Million – Up 10.6% Y/Y •   FY25 Gross Margin 44.6% – Up 60 Basis Points Y/Y•  FY25 GAAP Net Loss...

Coveo Named a Leader in the 2025 Gartner® Magic Quadrant™ for Search and Product Discovery

Coveo Named a Leader for the Second Consecutive Year MONTREAL and SAN FRANCISCO, June 26, 2025 /CNW/ - Coveo, the leader in AI-Relevance, delivering best-in-class...

Coveo Named a Leader in the 2025 Gartner® Magic Quadrant™ for Search and Product Discovery

Coveo Named a Leader for the Second Consecutive Year MONTREAL and SAN FRANCISCO, June 26, 2025 /PRNewswire/ - Coveo, the leader in AI-Relevance, delivering best-in-class...

LSPACE Adopts Centric PLM to Streamline Design, Development and Boost Collaboration

California-based beachwear lifestyle brand unifies teams and drives efficiency to speed new products to market with Centric Software CAMPBELL, Calif., June 26, 2025 /PRNewswire/ --...

EVA Pharma and BioPharma Town – Qiantang District, Hangzhou Sign a Strategic Cooperation Agreement

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office 
EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform...

Miracle Made Silver-Infused Sheets Gain Momentum as Clean Sleep Innovation Expands Across U.S. Market

Silver-Infused Bedding Innovation Gains Ground as Miracle Made® Expands U.S. Reach With Bacteria-Resistant, Temperature-Regulating Sheets Supporting Modern Sleep Hygiene 
Silver-Infused Bedding Innovation Gains Ground as Miracle Made® Expands U.S. Reach With Bacteria-Resistant, Temperature-Regulating Sheets Supporting Modern Sleep Hygiene

Nimanode Presale Skyrockets, over 28% Allocation Scooped as Major Investors Flock to the Potential 10X on XRP

LEEDS, United Kingdom, June 26, 2025 (GLOBE NEWSWIRE) -- The highly anticipated Nimanode (NMA) Presale has so far surpassed expectations, rapidly filling its presale allocation with 28% already scooped so far from its softcap which has fuelled intense investor FOMO.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers